Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (The Global Registry of Acute Coronary Events [GRACE])

Goldberg, Robert J.; Currie, Kristen E.; White, Kami; Brieger, David; Steg, Philippe Gabriel; Goodman, Shaun G.; Dabbous, O.; Fox, Keith A.A.; Gore, Joel M.

doi:10.1016/j.amjcard.2003.10.006

Cited by 171 publications

(131 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Born out of the ongoing global registry of acute coronary events (GRACE)-a prospective observational study involving, at the time, 94 hospitals across 14 countries, including Australia, with 43,810 patients-GRACE has been used to assess myriad outcomes in ACS. 4 The GRACE risk model uses age, heart rate, systolic blood pressure, creatinine, Killip Class of cardiac heart failure, and ACS presentation factors to establish risk and can be used in conjunction with the NHF/CSANZ guidelines to direct treatment in ACS.…”

Section: Guidelines Adjuvant Tools and The Australian Experience Of mentioning

confidence: 99%

“…3 Tools in risk stratification, like the GRACE risk model could help guide clinicians in triage, prognostication, and management of patients with ACS. [3][4] This improvement to in-hospital assessment could consequently reduce morbidity and mortality in ACS patients. Another concern has been raised regarding the management of NSTEACS-HR and IR.…”

Section: Approaches To Improving Outcomesmentioning

confidence: 99%

“…Failure to stratify risk in these patients has been implicated as the cause of this poorer outcome. [3][4] The existing risk stratification tools may be useful in increasing early treatment of patients, resulting in improved outcomes in NSTEACS. Use of these tools in clinical trials on patients presenting with ACS is advised to assess their usefulness in treatment, particularly in the NSTEACS-HR and IR groups.…”

Section: Approaches To Improving Outcomesmentioning

confidence: 99%

See 2 more Smart Citations

Acute coronary syndrome in Australia

Nadel¹,

Hewitt²,

Horton³

2017

AMJ

View full text Add to dashboard Cite

show abstract

Section: Guidelines Adjuvant Tools and The Australian Experience Of mentioning

confidence: 99%

Section: Approaches To Improving Outcomesmentioning

confidence: 99%

Section: Approaches To Improving Outcomesmentioning

confidence: 99%

See 1 more Smart Citation

Acute coronary syndrome in Australia

Nadel¹,

Hewitt²,

Horton³

2017

AMJ

View full text Add to dashboard Cite

show abstract

“…The 6-month mortality rate following infarction has been reported as 4.8% for STEMI and 6.2% for NSTEMI in an international registry involving 14 countries (Goldberg et al, 2004). Other studies have also shown an adverse prognosis for NSTEMI compared with STEMI patients at 12 months post-infarction (Terkelsen et al, 2005;Montalescot et al, 2007).…”

Section: Epidemiology Of Coronary Artery Disease 15mentioning

confidence: 99%

Epidemiology of Coronary Artery Disease

Beltrame¹,

Dreyer²,

Tavella³

2012

Coronary Artery Disease - Current Concepts in Epidemiology, Pathophysiology, Diagnostics and Treatment

View full text Add to dashboard Cite

“…[1][2][3][4][5][6][7][8] These data primarily come from registries of non-ST-elevation ACS and myocardial infarction (MI) where management is highly technical and complex. [2][3][4][9][10][11] Regional differences in noncomplex CV care required for hypertension and diabetes management have also been documented.…”

Section: Introductionmentioning

confidence: 99%

Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR‐Trandolapril Study (INVEST)

Zineh

Cooper‐DeHoff

Wessel

et al. 2005

Clinical Cardiology

View full text Add to dashboard Cite

Background: The INternational VErapamil SR‐Trandolapril Study (INVEST), a prospective, randomized, antihypertensive trial, found that two different medication regimens produced similar blood pressure (BP) control with equivalent cardiovascular (CV) outcomes (death from any cause, nonfatal myocardial infarction [MI], or nonfatal stroke). Hypothesis: The study was undertaken to investigate whether differences exist by global regions in demographics, treatment, and outcomes in the INVEST trial. Methods: Data were analyzed for 22,576 patients with stable coronary artery disease (CAD) enrolled in INVEST. We investigated differences in patient characteristics, treatment approaches, BP control, and clinical outcomes by creating three global regions based on geographical location: Northern Americas (NA), Caribbean (CA), and Eurasia (EA). Results: We observed significant regional differences in patient characteristics, treatment patterns, BP control, and CV outcomes. At baseline, patients from NA were older and had greater body mass index, higher rates of diabetes, peripheral vascular disease, and coronary revascularization, but lower rates of MI or left ventricular hypertrophy than patients in CA and EA. At 24 months, there were regional differences in both study and nonstudy antihypertensive drug use. Despite having higher mean baseline BP, patients from CA and EA achieved lower mean systolic BP throughout study follow‐up. Furthermore, patients from both CA and EA had lower rates of all‐cause mortality, fatal or nonfatal MI, fatal or nonfatal stroke, and newly diagnosed diabetes than patients from NA. Conclusions: In INVEST, regional differences in medication utilization, BP control, and CV outcomes were identified. These disparities warrant further investigation to define appropriate care for patients with hypertension and stable CAD from an international public health perspective.

show abstract

Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (The Global Registry of Acute Coronary Events [GRACE])

Cited by 171 publications

References 9 publications

Acute coronary syndrome in Australia

Acute coronary syndrome in Australia

Epidemiology of Coronary Artery Disease

Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR‐Trandolapril Study (INVEST)

Contact Info

Product

Resources

About